Laboratoire de Chimie et Biochimie
Pharmacologiques et Toxicologiques (LCBPT)
CNRS UMR 8601
Université Paris Descartes
45 Rue des Saints Pères
75270 Paris Cedex 06
France

Mathieu Rodero

Research Scientist, CNRS

Since my PhD, I have been studying immunology in various models of mice and human inflammatory diseases. Inspired by my recent work on human interferonopathies, a set of diseases characterised by miss regulated and sustained production of type I interferon, I have decided in 2018 to join the team of “Chemistry, Biology, Modelling and Immunology for Therapy” in order to foster the development of new therapy and diagnosis tools for these conditions. Our projects, based on a collaborative, multidisciplinary and translational approaches combine access to state of the art technology to material of patients with rare diseases.

Curriculum Vitae

Education
2017: Accreditation to direct research (HDR) at Paris Descartes University (Paris 5), Paris, France
2005 – 2008: PhD in Immunology with honours at the Orsay University (Paris 11), Paris, France
2004 – 2005: Master’s degree in Cell Signaling at the Orsay University (Paris 11), Paris, France
2002 – 2004: Bachelor’s degree in Cellular Biology and Physiology at the Poitiers University, Poitiers, France
2000 – 2002: Superior Laboratory Technician Diploma in Biology and Biotechnology

Research Experiences
2019 Senior Researcher at CNRS : Laboratoire de Chimie et Biochimie pharmacologiques et toxicologiques, UMRS8601, Faculté des St Pères, Paris, France
– Pathophysiology of juvenile dermatomyositis
– Identification and validation of new immune-modulator
– Characterisation of CXCR4 mediated anti inflammatory mechanisms

2018 -Post-doctoral fellow: Laboratoire de Chimie et Biochimie pharmacologiques et toxicologiques, UMRS8601, Faculté des St Pères, Paris, France
– Identification and validation of new immune-modulator
– Development of personalised diagnostic test for auto inflammatory and autoimmune paediatric diseases

2014 – 2017 -Post-doctoral fellow: Laboratory of neurogenetics and neuroinflammation,
Inserm U1163, Imagine Institut, Paris, France
– Development of new therapies for interferon related monogenic diseases
– Identification of new interferonopathies
– Characterisation of the cellular response of patients following new anti-inflammatory treatment strategy
– Development of new diagnosis tool for interferonopathies

2013 – 2014 – Post-doctoral fellow: Centre d’Immunologie et des Maladies Infectieuses, Inserm U1135, Pitié Salpêtrière hospital, Paris, France
– Monitoring of the immune surveillance at steady state.
– Improvement of chemotherapies effect by modulation of macrophages function
– Improvement of defective skin wound healing by modulation of macrophages function

2009 – 2012 – Post-doctoral fellow: Laboratory of Experimental Dermatology, UQCCR,Royal and Woman Brisbane Hospital in Brisbane, Australia
– Role of macrophages in skin wound healing inflammation
– Role of macrophages in UVB induced melanocyte response
– EPC differentiation during wound healing
– Identification of new prognosis marker for grade II melanoma

2005 – 2009 – PhD and Post-doctoral fellow: under the supervision of Dr Christophe Combadière. Laboratoire d’immunologie cellulaire et infection, InsermU945, Pitié Salpêtrière Hospital, Paris, France
– Role of the chemokines in the modulation of the physiopathological functions of macrophages in tumor, arthrosclerosis and ischemia model.

Grants, Awards and Recognitions
2018: Recipient of the Christian Nezelof – Imagine Price 2018
2017: Front Cover of the Journal of Experimental Medicine of May 2017
2016: Rare Diseases Foundation PI € 25 000
2014: Selected for July 2014 “Meet the investigator” by the Journal of Investigative Dermatology
2013: Selected for ESDR Academy for Future Leaders in Dermatology
2010: University of Queensland Early Career Researcher Grant PI AU$ 25 000
2010: University of Queensland New Staff Research Start−Up Grant PI AU$ 12 000
2010: Scientific Research Fund from The Australasian College of Dermatologists PI AU$ 15 000
2009: Recipient of a European Post -doctoral fellowship Innochem
2006: Recipient of 3 years PhD Fellowship from Cancéropôle Ile de France

Last 3 years

De Luca C et al, Expanding the clinical spectrum of Fowler syndrome: Three siblings with survival into adulthood and systematic review of the literature. Clin Genet. 2020

Stefia LV et al, Secretome Components from Faecalibacterium prausnitzii Strains A2-165 and AHMP21 Modulate Cutaneous Wound Inflammation. J Invest Dermatol. 2020

Smith C et al, Biallelic mutations in NRROS cause an early onset lethal microgliopathy. Acta Neuropathol. 2020

Williams J et al, Neuromyelitis optica in patients with increased interferon alpha concentrations. Lancet Neurol. 2020

Rice GI et al, Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. Hum Mutat. 2020

Gitiauc C, […], Bader Meunier B* and Rodero MP* ,Inhibition of IFNa secretion in cells from patients with JDM under TBK1 treatment revealed by Single Molecular Assay technology . Rheumatology , 2019

Melki I et al, Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. Rheumatology 2019

Van Eyck L et al, Biallelic mutations in MTPAP associated with a lethal encephalopathy. Neuropediatrics 2019.

Melki I, […],  Rodero MP* and Bader Meunier B*. Circulating interferon-α measured with a highly sensitive assay as a biomarker for juvenile inflammatory myositis activity. Arthritis Rheumatol, 2019

Smith N, Rodero MP et al. Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment.. ScienceAdvences, 2019.

Gratia M, Rodero MP et al. Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS.. J Exp Med, 2019

Rice GI et al. Reverse Transcriptase Inhibitors in Aicardi-Goutières Syndrome. N Engl J Med, 2018.

Hernandez N, et al. Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency.. J Exp Med, 2018.

Ruaud L, Rice GI, Cabrol C, Piard J, Rodero MP et al. Autosomal dominant early-onset spastic paraparesis with brain calcification due to IFIH1 gain-of-function. Human Mutation, 2018.

Ladislau L et al. Jak inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018.

Llibre A, Bondet V, Rodero MP et al. Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-Linked Immunosorbent Assay for Human Interferon-α. Jove 2018.

All Publications

De Luca C et al, Expanding the clinical spectrum of Fowler syndrome: Three siblings with survival into adulthood and systematic review of the literature. Clin Genet. 2020

Stefia LV et al, Secretome Components from Faecalibacterium prausnitzii Strains A2-165 and AHMP21 Modulate Cutaneous Wound Inflammation. J Invest Dermatol. 2020

Smith C et al, Biallelic mutations in NRROS cause an early onset lethal microgliopathy. Acta Neuropathol. 2020

Williams J et al, Neuromyelitis optica in patients with increased interferon alpha concentrations. Lancet Neurol. 2020

Rice GI et al, Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. Hum Mutat. 2020

Gitiauc C, […], Bader Meunier B* and Rodero MP* ,Inhibition of IFNa secretion in cells from patients with JDM under TBK1 treatment revealed by Single Molecular Assay technology . Rheumatology, 2019

Melki I et al, Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. Rheumatology 2019

Van Eyck L et al, Biallelic mutations in MTPAP associated with a lethal encephalopathy. Neuropediatrics 2019.

Melki I, […],  Rodero MP* and Bader Meunier B*. Circulating interferon-α measured with a highly sensitive assay as a biomarker for juvenile inflammatory myositis activity. Arthritis Rheumatol, 2019

Smith N, Rodero MP et al. Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment.. ScienceAdvences, 2019.

Gratia M, Rodero MP et al. Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS.. J Exp Med, 2019.

Rice GI et al. Reverse Transcriptase Inhibitors in Aicardi-Goutières Syndrome.. N Engl J Med, 2018.

Hernandez N, et al. Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency.. J Exp Med, 2018.

Ruaud L, Rice GI, Cabrol C, Piard J, Rodero MP et al. Autosomal dominant early-onset spastic paraparesis with brain calcification due to IFIH1 gain-of-function. Human Mutation, 2018.

Ladislau L et al. Jak inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018.

Llibre A, Bondet V, Rodero MP et al. Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-Linked Immunosorbent Assay for Human Interferon-α. Jove 2018.

Rodero MP et al. Type I interferon mediated autoinflammation due to DNase II deficiency. Nat Commun 2017.

Lee J, Rodero MP et al. Interleukin-23 regulates interleukin-17 expression in wounds, and its inhibition accelerates diabetic wound healing through the alteration of macrophage polarization. FASEB J 2017.

Gitiaux C, et al. Myogenic progenitor cells exhibit IFN type I-driven pro-angiogenic properties and molecular signature during juvenile dermatomyositis. Arthritis Rheumatol, 2017.

Fremond ML*, Uggenti, C*, […], Rodero MP. TBK1 / IKKE blockade inhibits mutant STING mediated inflammatory response in patient cells. Arthritis Rheumatol, 2017.

Rodero MP* et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med, 2017.

Amsellem V, Abid S, Poupel L, Parpaleix A, Rodero MP* et al. Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 Chemokine Systems in Hypoxic Pulmonary Hypertension Am J Respir Cell Mol Biol, 2017.

Melki I, Rose Y, […], Rodero MP* Crow YJ*.  Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J Allergy Clin Immunol, 2017.

Rice GI, Melki I, Frémond ML, Briggs TA, Rodero MP et al. Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. J Clin Immunol, 2017.

Patel J, Seppanen EJ, Rodero MP et al Functional Definition of Progenitors Versus Mature Endothelial Cells Reveals Key SoxF-Dependent Differentiation Process. CIRCULATION, 2017.

Rodero MP et al, JAK inhibition in STING-associated interferonopathy. ARD, 2016.

Fremond ML*, Rodero MP* et al,          Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol 2016.

Jenkinson EM, Rodero MP et al, Mutations in SNORD118 cause cerebral microangiopathy leukoencephalopathy with calcifications and cysts. Nature Genetics 2016.

Uettwiller F, Sarrabay G, Rodero MP et al, ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. RMD Open, 2016.

Rowe CJ, Tang F, Hughes MC, Rodero MP et al, Molecular markers to complement sentinel node status in predicting survival in patients with high risk locally invasive melanoma. Int J Cancer. 2016.

Lee J ;Seppanen E, Patel J, Rodero MP and Khosrotehrani K, ST2 receptor invalidation maintains wound inflammation, delays healing and increases fibrosis. Exp Dermatol. 2015.

Rodero MP* et al : Immune surveillance of the lung by migrating tissue-monocytes. eLIFE. 2015.

Y. Handoko, Rodero MP et al. Lack of Evidence From a Transgenic Mouse Model that the Activation and Migration of Melanocytes to the Epidermis after Neonatal UVR Enhances Melanoma Development. J. Invest. Dermathol, 2015 Jun .

Hamond P, Rodero MP et al. Tracking mouse bone marrow monocytes in vivo. JOVE, 2015 Feb 27;(96):e52476

Rodero MP et al, In vivo imaging reveals a pioneer wave of monocyte recruitment into mouse skin wounds. Plos one, 2014 Oct.

Rodero MP*, H. Y. Handoko* et al. Differential effects of ultraviolet irradiation in neonatal versus adult mice are not explained by defective macrophage or neutrophil infiltration. J. Invest. Dermathol, 2014 Jul.

Rodero MP et al. Control of Both Myeloid Cell Infiltration and Angiogenesis by CCR1 Promotes Liver Cancer Metastasis Development in Mice. Neoplasia, 2013 Jun.

  1. Y. Handoko*, Rodero MP* et al. UVB-induced melanocyte proliferation in neonatal mice driven by CCR2-independent recruitment of Ly6c(low)MHCII(hi) macrophages. J. Invest. Dermathol, 2013 Jul;

Rodero MP et al, Wound-associated macrophages control collagen 1α2 transcription during the early stages of skin wound healing. Exp Dermatol. 2013 Feb;22.

Rodero MP et al. Reduced Il17a expression distinguishes a Ly6clow MHCIIhi macrophage population promoting wound healing. J. Invest. Dermathol, 2013 Mar.

Rodero MP et al. Increase lymphangiogenesis in melanoma during pregnancy: correlation with the prolactin signalling pathway Journal of the European Academy of Dermatology and Venereology 2012 May 2

Ramos MV, Auvynet C, Poupel L, Rodero M et al Chemokine Receptor CCR1 Disruption Limits Renal Damage in a Murine Model of Hemolytic Uremic Syndrome. Am J Pathol 2012.

Cochain C*, Rodero MP* et al. Regulation of monocyte subsets systemic levels by distinct chemokine receptors controls postischemic neovascularization. Cardiovasc Res 2010 Oct 1.

El Hallani S, Ducray F, Idbaih A, Marie Y, Boisselier B, Colin C, Laigle-Donadey F, Rodero M et al. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology 2009.

Dorgham K, Ghadiri A, Hermand P, Rodero M et al. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol 2009.

Rodero M et al. Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol 2008.

Raoul W, Keller N, Rodero M et al. Role of the chemokine receptor CX3CR1 in the mobilization of phagocytic retinal microglial cells. J Neuroimmunol 2008.

Guedj M, Bourillon A, Combadieres C, Rodero M et al. Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. Hum Mutat 2008.

Combadiere C, Potteaux S, Rodero M et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008

Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Criniere E, Rodero M et al. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet, 2008.

El Hallani S, Marie Y, Idbaih A, Rodero M et al. No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J Neurooncol 2007.

Combadiere C, Feumi C, Raoul W, Keller N, Rodero M et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 2007.

Rodero M, et al. Melanoma susceptibility and progression: Association study between polymorphisms of the chemokine (CCL2) and chemokine receptors (CX3CR1, CCR5). J Dermatol Sci 2007.

Nadif R, Mintz M, Rivas-Fuentes S, Jedlicka A, Lavergne E, Rodero M et al. Polymorphisms in chemokine and chemokine receptor genes and the development of coal workers’ pneumoconiosis. Cytokine 2006.

Reviews, comments and book chapter:

Gies  V et al. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontieres Immunology. 2020

Loyher PL, Rodero MP et al. Role of Chemokines and Chemokine Receptors in Cancer, Cancer Immunology, Springer, 2020.

Della-mina E, Rodero MP and Crow YJ: Polymorphisms in IFIH1 – the good and the bad. Nat Immunol. 2017

Rodero MP and Crow YJ: Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. JExpMed 2016

Rodero MP and Crow YJ: cGMP-AMP synthase paves the way to autoimmunity. PNAS 2015

Rice GI, Rodero MP, Crow YJ: Human disease phenotypes associated with mutations in TREX1. J C Immunol. 2015.

Rodero MP et al. Role of chemokines and chemokine receptors in cancers. Cancer Immunology: Translational Medicine from Bench to Bedside, Springer, 2014.

Rodero MP and Khosrotehrani K. Skin wound healing modulation by macrophages. IJCEP 2010

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.